Lindis Blood Care GmbH

Lindis Blood Care GmbH is a Germany-based medical technology startup striving to revolutionize oncological blood management. With the ambition of establishing a new gold standard in this field, the company has developed CATUVAB®, a groundbreaking medical device that integrates proven filter technologies with a trifunctional antibody to effectively eliminate EpCAM-positive cancer cells from intraoperative blood. This innovative approach holds the promise of enabling autologous blood transfusion during cancer surgeries, thereby mitigating the adverse effects associated with allogenic transfusions and enhancing treatment outcomes for cancer patients.

The latest milestone in Lindis Blood Care's journey was the Venture Round investment secured on 09 February 2022. The investment was led by BC Brandenburg Capital and HTGF | High-Tech Gruenderfonds, underscoring the confidence of prominent investors in the company's vision and technology. As a pioneering player in the Health Care sector since its establishment in 2010, Lindis Blood Care GmbH is well-positioned to make a significant impact in the field of oncological blood management and elevate the standard of care for cancer patients globally.